Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 12,500 Shares of Stock

Key Points

• Insider Timothy Rolph sold 12,500 shares of Akero Therapeutics stock for $616,250, which represents a 6.96% decrease in his ownership.
• Akero Therapeutics stock has experienced a 3.7% decrease, trading at $50.86, with a market capitalization of $4.05 billion.
• The stock currently holds an average consensus rating of "Buy" among analysts, with an average target price of $81.57.

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 12,500 shares of Akero Therapeutics stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $49.30, for a total value of $616,250.00. Following the completion of the sale, the insider directly owned 167,124 shares of the company's stock, valued at approximately $8,239,213.20. This trade represents a 6.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Monday, July 7th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $51.09, for a total value of $638,625.00.
• On Wednesday, June 18th, Timothy Rolph sold 1,129 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.84, for a total value of $61,914.36.
• On Tuesday, June 10th, Timothy Rolph sold 2,358 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.00, for a total value of $127,332.00.
• On Thursday, June 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.49, for a total value of $668,625.00.
• On Friday, June 6th, Timothy Rolph sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $55.04, for a total value of $1,376,000.00.

Akero Therapeutics Price Performance

NASDAQ:AKRO traded up $0.01 during mid-day trading on Friday, reaching $50.46. The stock had a trading volume of 1,059,275 shares, compared to its average volume of 1,036,138. The firm has a 50 day moving average price of $52.34 and a two-hundred day moving average price of $46.88. The stock has a market capitalization of $4.02 billion, a P/E ratio of -25.88 and a beta of -0.28. Akero Therapeutics, Inc. has a one year low of $21.34 and a one year high of $58.40. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.80 and a current ratio of 16.80.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($0.97) by $0.11. During the same period in the previous year, the business posted ($0.81) EPS. As a group, analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Institutional Investors Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AKRO. RTW Investments LP lifted its stake in Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after acquiring an additional 940,388 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Akero Therapeutics by 11.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,817,091 shares of the company's stock worth $194,997,000 after purchasing an additional 495,119 shares in the last quarter. Vanguard Group Inc. raised its holdings in Akero Therapeutics by 14.2% in the 1st quarter. Vanguard Group Inc. now owns 4,230,644 shares of the company's stock worth $171,256,000 after purchasing an additional 526,233 shares in the last quarter. Deep Track Capital LP raised its holdings in Akero Therapeutics by 116.0% in the 4th quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after purchasing an additional 800,216 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in Akero Therapeutics by 93.3% in the 1st quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock worth $46,786,000 after purchasing an additional 557,794 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on AKRO shares. Citigroup dropped their price target on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Bank of America lifted their price target on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research report on Tuesday, May 27th. Cowen started coverage on Akero Therapeutics in a research report on Monday, August 4th. They set a "buy" rating for the company. Finally, TD Cowen started coverage on Akero Therapeutics in a research report on Monday, August 4th. They set a "buy" rating and a $76.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $81.57.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.